TAp63 is shown to drive the expression of IFN-γ-related genes in ER- (estrogen receptor-negative) wild-type TP53 (wtTP53) breast cancers, where it binds to promoters of IFN-γ signaling genes. This evidence concerns the gene TP53 and breast carcinoma.